Pasar al contenido principal

SINTESIS DE CANDIDATOS A FARMACOS INNOVADORES CONTRA ENFERMEDADES NEURODEGENERATIVAS Y DOLOR

PID2023-147004OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor

  • Oken, Adam C.
  • Turcu, Andreea L.
  • Tzortzini, Eva
  • Georgiou, Kyriakos
  • Nagel, Jessica
  • Westermann, Franka G.
  • Barniol Xicota, Marta
  • Seidler, Jonas
  • Kim, Ga-Ram
  • Lee, So-Deok
  • Nicke, Annette
  • Kim, Yong-Chul
  • Müller, Christa E.
  • Kolocouris, Antonios
  • Vázquez, Santiago
  • Mansoor, Steven E.
The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential., We thank O. Davulcu, C. Yoshioka, and C. López at PNCC for access and microscopy assistance. Electron microscopy grid screening was performed at the Multiscale Microscopy Core within Oregon Health & Science University (OHSU). The authors would like to acknowledge the contributions of the OHSU Biophysics Shared Resource Core (Research Resource ID: RRID: SCR_022744) in facilitating this work. We thank L. Anson for comments on the manuscript. A portion of this research was supported by NIH grant U24GM129547 and performed at the PNCC at OHSU and accessed through EMSL (grid.436923.9), a DOE Office of Science User Facility sponsored by the Office of Biological and Environmental Research. This research was supported by the National Heart, Lung, and Blood Institute (R00HL138129, S.E.M.), the National Institute of General Medical Sciences (DP2GM149551, S.E.M.), and the American Heart Association (24PRE1195450, A.C.O.). Part of this work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033 and by ERDF/EU: grant PID2023-147004OB-I00 (to S.V.). The Kolocouris Lab thanks Chiesi Hellas for funding (SERG No. 10354). C.E.M. is grateful to the German Federal Ministery of Education and Research (BMBF) for support (Biopharma Neuroallianz, 0315606B), the Deutsche Forschungsgemeinschaft (SFB 1328) for supporting this work, and the COST Action CA21130 "P2X receptors as a therapeutic opportunity (PRESTO)". We thank Andhika B. Mahardhika for support in some of the biological experiments. A.N. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 335447717 - SFB 1328, project A15. The Mansoor Lab would like to thank Steve Janik and Sheryl Manning, Barbara Allen and Jim Batzer, and Randy and Barbara Lovre for their generous support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M. Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., this work was funded by the spanish Ministerio de ciencia, innovación y universidades, Miciu/aei/10.13039/501100011033: Grants PiD2020-118127RB-i00 and PiD2023-147004OB-i00 (to s.V.), PiD2019-108691RB-i00 (to e.J.c.),PDc2021-121096 (to M.P. and c.s.), PiD2021-127693OB-i00 (to c.G.), PiD2022-141676NB-i00 (to F.F.);PiD2021-129034NB-i00 and PDc2022-133950-i00 (to s.O.); the Generalitat de catalunya (2021 sGR 00357 and 2021sGR 00487); the european Research council (eRc-2015-stG-679001-NetMoDezyme and eRc-2022-coG-101088032 tos.O.); the Xunta de Galicia (eD431c 2022/20); and the european Regional Development Fund (eRDF); Ministry ofscience and innovation, spain, with funds from the european union NextGenerationeu (PRtRc17.i1) and theautonomous community of Galicia within the framework of the 2023 Biotechnology Plan applied to health (to M.i.l.and J.B.). Partial support was provided by Nih-Niehs River award R35 es030443 and, Nih-Niehs superfund ProgramP42 es004699 to B.D.h. the content is solely the responsibility of the authors and does not necessarily represent theofficial views of the National institutes of health. M.R.c. was granted access to i24 beamline by the Diamond lightsource for (proposal number: MX32787). s.c. and a.l.t. received PhD fellowships from the universitat de Barcelona(aPiF grant) and the spanish Ministerio de educación, cultura y Deporte (FPu15/00889 grant), respectively. a.B.-M.,c.e., and M.s.-c. were supported by the Research Personnel training Program (FPi grants PRe2019-087468,PRe2022-104952, and PRe2020-096203, respectively) of the spanish Ministerio de ciencia, innovación y universidades(Miciu) and agencia estatal de investigación (aei). Q.Q. is funded by the King’s-china scholarship council PhDscholarship programme. F.F. received spanish MiciNN for a Ramón y cajal fellowship (RYc2020-029552-i). c.c.-t.received science Postdoctoral Fellowship from a schmidt Futures program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain [Dataset]

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033: Grants PID2020-118127RB-I00 and PID2023-147004OB-I00 (to S.V.), PID2019-108691RB-I00 (to E.J.C.), PDC2021-121096 (to M.P. and C.S.), PID2021-127693OB-I00 (to C.G.), PID2022-141676NB-I00 (to F.F.); PID2021-129034NB-I00 and PDC2022-133950-I00 (to S.O.); the Generalitat de Catalunya (2021 SGR 00357 and 2021 SGR 00487); the European Research Council (ERC-2015-StG-679001-NetMoDEzyme and ERC-2022-CoG-101088032 to S.O.); the Xunta de Galicia (ED431C 2022/20); and the European Regional Development Fund (ERDF); Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health (to M.I.L. and J.B.). Partial support was provided by NIH-NIEHS River Award R35 ES030443 and, NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.R.C. was granted access to I24 beamline by the Diamond Light Source for (proposal number: MX32787). S.C. and A.L.T. received PhD fellowships from the Universitat de Barcelona (APIF grant) and the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/00889 grant), respectively. A.B.-M., C.E., and M.S.-C. were supported by the Research Personnel Training Program (FPI grants PRE2019-087468, PRE2022-104952, and PRE2020-096203, respectively) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI). Q.Q. is funded by the King’s-China Scholarship Council PhD Scholarship programme. F.F. received Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). C.C.-T. received Science Postdoctoral Fellowship from a Schmidt Futures program., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor

  • Oken, Adam C.
  • Turcu, Andreea L.
  • Tzortzini, Eva
  • Georgiou, Kyriakos
  • Nagel, Jessica
  • Westermann, Franka G.
  • Barniol Xicota, Marta
  • Seidler, Jonas
  • Kim, Ga-Ram
  • Lee, So-Deok
  • Nicke, Annette
  • Kim, Yong-Chul
  • Müller, Christa E.
  • Kolocouris, Antonios
  • Vázquez, Santiago
  • Mansoor, Steven E.
The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential., We thank O. Davulcu, C. Yoshioka, and C. López at PNCC for access and microscopy assistance. Electron microscopy grid screening was performed at the Multiscale Microscopy Core within Oregon Health & Science University (OHSU). The authors would like to acknowledge the contributions of the OHSU Biophysics Shared Resource Core (Research Resource ID: RRID: SCR_022744) in facilitating this work. We thank L. Anson for comments on the manuscript. A portion of this research was supported by NIH grant U24GM129547 and performed at the PNCC at OHSU and accessed through EMSL (grid.436923.9), a DOE Office of Science User Facility sponsored by the Office of Biological and Environmental Research. This research was supported by the National Heart, Lung, and Blood Institute (R00HL138129, S.E.M.), the National Institute of General Medical Sciences (DP2GM149551, S.E.M.), and the American Heart Association (24PRE1195450, A.C.O.). Part of this work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033 and by ERDF/EU: grant PID2023-147004OB-I00 (to S.V.). The Kolocouris Lab thanks Chiesi Hellas for funding (SERG No. 10354). C.E.M. is grateful to the German Federal Ministery of Education and Research (BMBF) for support (Biopharma Neuroallianz, 0315606B), the Deutsche Forschungsgemeinschaft (SFB 1328) for supporting this work, and the COST Action CA21130 "P2X receptors as a therapeutic opportunity (PRESTO)". We thank Andhika B. Mahardhika for support in some of the biological experiments. A.N. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 335447717 - SFB 1328, project A15. The Mansoor Lab would like to thank Steve Janik and Sheryl Manning, Barbara Allen and Jim Batzer, and Randy and Barbara Lovre for their generous support.